Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Aethlon Medical, Inc. (AEMD)

5.44 -0.08 (-1.45%)
At close: October 30 at 4:00:01 PM EDT
5.31 -0.13 (-2.39%)
After hours: October 30 at 4:38:37 PM EDT
Chart Range Bar
Loading chart for AEMD
Chart does not reflect overnight price.
  • Previous Close 5.52
  • Open 5.30
  • Bid 4.74 x 200
  • Ask 5.26 x 100
  • Day's Range 5.15 - 5.48
  • 52 Week Range 1.41 - 26.20
  • Volume 27,671
  • Avg. Volume 2,567,430
  • Market Cap (intraday) 8.726M
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) --
  • EPS (TTM) -32.97
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 13.25

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.

www.aethlonmedical.com

9

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AEMD
60.72%
S&P 500 (^GSPC)
10.73%

1-Year Return

AEMD
79.96%
S&P 500 (^GSPC)
11.11%

3-Year Return

AEMD
99.06%
S&P 500 (^GSPC)
81.91%

5-Year Return

AEMD
99.96%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue --
Earnings -1.88M
Profit Margin 0.00%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

-2M
-2M
-1M
-500K
0
0.0%

Analyst Insights

View More

Analyst Price Targets

1.50 Low
13.25 Average
5.44 Current
25.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2025
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Neutral
Price Action Maintains
Price Target 1.5 -> 1.5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -76.68%

  • Return on Equity (ttm)

    -160.91%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -6.94M

  • Diluted EPS (ttm)

    -32.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.93M

  • Total Debt/Equity (mrq)

    7.07%

  • Levered Free Cash Flow (ttm)

    -4.79M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: